<DOC>
	<DOC>NCT02043197</DOC>
	<brief_summary>Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin速 on the severity of anxiety and depression, sleep state, and cognitive function.</brief_summary>
	<brief_title>Fevarin速 Effectiveness in Treatment of Depression in Patients With Neurological Disorder</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Fluvoxamine</mesh_term>
	<criteria>Outpatients with neurological disorders and mild or moderate symptoms of depression with HADS depression scale score of 8 and higher. Fevarin速 prescribed not earlier than 7 days before Visit 1. Labeled contraindications to Fevarin速, psychotic symptoms and/or suicidal ideation, schizophrenia, bipolar disorder, schizoaffective disorder, severe dementia, alcohol or drug abuse, acute neurological disorders.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Depression,</keyword>
	<keyword>depressive symptoms,</keyword>
	<keyword>major depressive disorder,</keyword>
	<keyword>Fevarine,</keyword>
	<keyword>fluvoxamine,</keyword>
	<keyword>cognitive function,</keyword>
	<keyword>neurological disorders,</keyword>
	<keyword>sleep state</keyword>
</DOC>